Association between selective serotonin reuptake inhibitor and risk of peripheral artery disease in diabetes mellitus: Propensity score matching and landmark analysis. Issue 18 (6th May 2022)

• Record Type: Journal Article
• Authors: Chen, Kai-Hua; Wang, Ting-Yao; Lee, Chuan-Pin; Yang, Yao-Hsu; McIntyre, Roger S.; Subramaniapillai, Mehala; Lee, Yena; Chen, Vincent Chin-Hung
• Editors: Găman., Mihnea-Alexandru
• Is Part Of: Medicine. Volume 101:Issue 18(2022)
• Page Start: e29202
• Publication Date: 2022-05-06
• Subjects: antidepressant -- diabetes mellitus -- peripheral artery disease -- SSRI; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029202
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: An increasing number of studies have demonstrated the bidirectional hemostatic effect of selective serotonin reuptake inhibitors (SSRIs) on the risk of cerebrovascular and cardiovascular diseases. However, no previous study has focused on the relationship between SSRI and the risk of peripheral artery disease (PAD) in diabetes mellitus (DM). We sought to evaluate the association between SSRIs and the PAD risk in individuals with DM. We conducted a retrospective, population-based cohort study using data from the Longitudinal Health Insurance Database from 1999 to 2010 in Taiwan. A total of 5049 DM patients were included and divided into 2 groups: DM with SSRI users and DM with SSRI non-users. Propensity score matching and 1-year landmark analysis were used for our study design. Stratified Cox proportional hazard regressions were used to analyze the hazard ratio of the PAD risk in certain subgroups. DM with SSRI users did not affect the PAD risk compared to DM with SSRI non-users. These findings were consistent with all sensitivity analyses (i.e., age, sex, SSRI doses, antithrombotic medication use, and medical and psychiatric comorbidities). In this study, we found that there was no significant difference of PAD risk between DM with SSRI users and DM with SSRI non-users. DM with SSRI user did not affect PAD risk across any SSRI dose, age, sex, antithrombotic medications, and multiple comorbidities in the subgroup analysis.